Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Completes Acquisition of Orchid Cellmark

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said it has completed its $85.4 million buy of Orchid Cellmark.

As of 4 p.m., EST, Dec. 15, the expiration of a subsequent offering period, stockholders of Orchid had tendered an additional 217,184 shares of Orchid's common stock during the subsequent offering period, the depositary for the tender offer advised LabCorp. The number of shares acquired during this period combined with the number of shares accepted for payment during the initial offering period represents an aggregate of 87.2 percent of Orchid's currently outstanding shares.

Orchid is now a subsidiary of LabCorp and its shares will stop trading on Nasdaq.

The deal was announced in April but was delayed several times as the US Federal Trade Commission requested additional information.

In early morning trading, shares of LabCorp on the New York Stock Exchange were up 1 percent to $82.27.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.